Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CSF in Relapsed/Refractory AML Salvage Chemotherapy
NCT02427919Phase 3Unknown
- Sponsor
- Seoul St. Mary's Hospital
- Start
- Mar 2015
- Primary completion
- Dec 2017
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 3 trial of filgrastim in acute myeloid leukemia (AML), sponsored by Seoul St. Mary's Hospital. Status: unknown.
02
Drugs
filgrastim
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02427919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02427919.